1. MI-773, a breaker of the MDM2/p53 axis, exhibits anticancer effects in neuroblastoma via downregulation of INSM1
- Author
-
Zheng Zhang, Gen Li, Juan-Juan Yu, Yongping Zhang, Yi Xie, Ran Zuo, Shuiyan Wu, Xiaolu Li, Jing-Jing Pan, Shaoyan Hu, Xin-Mei Liao, Jian Pan, Di Wu, Hai-Rong Wang, Zhi-Heng Li, Yanling Chen, Fang Fang, Yan-Fang Tao, Chen-Xi Feng, Jun Lu, Xinran Chu, Hai-Bo Cao, Jian-Wei Wang, and Zimu Zhang
- Subjects
Cancer Research ,Cell cycle checkpoint ,Chemistry ,Cell ,Articles ,Cell cycle ,Molecular medicine ,medicine.anatomical_structure ,Oncology ,Downregulation and upregulation ,Apoptosis ,Annexin ,medicine ,Cancer research ,Viability assay - Abstract
Neuroblastoma (NB) is a common pediatric malignancy associated with poor outcomes. Recent studies have shown that murine double minute2 homolog (MDM2) protein inhibitors are promising anticancer agents. MI-773 is a novel and specific antagonist of MDM2, however, the molecular mechanism of its anti-NB activity remains unclear. NB cell viability was measured by Cell Counting Kit-8 assay following MI-773 treatment. Cell cycle progression was analyzed using PI staining and apoptosis was assessed using Annexin V/PI staining. The molecular mechanisms by which MI-773 exerted its effects were investigated using a microarray. The results showed that disturbance of the MDM2/p53 axis by MI-773 resulted in potent suppression of proliferation, induction of apoptosis and cell cycle arrest in NB cells. In addition, microarray analysis showed that MI-773 led to significant downregulation of genes involved in the G(2)/M phase checkpoint and upregulation of hallmark gene associated with the p53 pathway. Meanwhile, knockdown of insulinoma-associated 1 decreased proliferation and increased apoptosis of NB cells. In conclusion, the present study demonstrated that MI-773 exhibited high selectivity and blockade affinity for the interaction between MDM2 and TP53 and may serve as a novel strategy for the treatment of NB.
- Published
- 2021